Top Story

Addition of lenalidomide to standard therapy fails to prolong PFS in multiple myeloma

February 8, 2016

Combination lenalidomide, melphalan and prednisone, followed by lenalidomide maintenance, did not significantly extend PFS or improve response rates compared with standard of care among transplant-ineligible patients with newly diagnosed multiple myeloma, according to the results of a randomized phase 3 study.

However, the novel combination appeared to reduce the rate of neuropathy, results showed.

In the Journals

Racial, treatment-related factors may influence bevacizumab efficacy in advanced cervical cancer

February 7, 2016
Use of Moore criteria may identify patients with advanced cervical cancer who may not benefit from treatment with bevacizumab, according to results of a study conducted…

Children’s Research Institute at Children’s Mercy appoints chief scientific officer

February 6, 2016
Tom Curran, PhD, FRS, has been hired as chief scientific officer and executive director of Children’s Research Institute at Children’s Mercy Kansas City.The…
Meeting News Coverage

Oncologists, PCPs disagree on who should provide cancer survivorship care

February 5, 2016
Oncologists and primary care physicians within the same integrated health system disagreed on who should ultimately manage care for survivors of cancer, according to…

ABIM continues to engage physicians on MOC updates

February 5, 2016
The ABIM has announced several new efforts aimed at including internists and subspecialists in the process of improving Maintenance of Certification assessments…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »

VIDEO: Genomic profiling, identification of mutations, leads to therapeutic developments

January 28, 2016
More »

Updates from Vienna 2015 – Highlights in Hematologic Malignancies

This activity is supported by an educational grant from Genentech, Inc.

The management of patients with hematologic malignancies—from diagnosis to treatment decisions—can represent a…
More »
Current Issues
View the Current Issue
HemOnc Today